SEC Comment Letter 0000000000-23-010316 to CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Sept. 19, 2023 · CIK: 0001962738 · Accession: 0000000000-23-010316

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-41666

Date

September 19, 2023

Author

Not clearly detected

Form

UPLOAD

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

United States securities and exchange commission logo September 19, 2023 Wei-Wu He Chief Executive Officer CASI Pharmaceuticals, Inc. 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road Chaoyang District Beijing, 100025 People’s Republic of China Re:CASI Pharmaceuticals, Inc. Form 20-F for the Fiscal Year December 31, 2022 File No. 001-41666 Dear Wei-Wu He: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Disclosure Review Program cc: Peter Huang

Show Raw Text

United States securities and exchange commission logo
September 19, 2023
Wei-Wu He
Chief Executive Officer
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing, 100025
People’s Republic of China
Re:CASI Pharmaceuticals, Inc.
Form 20-F for the Fiscal Year December 31, 2022
File No. 001-41666
Dear Wei-Wu He:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Disclosure Review Program
cc:       Peter Huang

SecProbe.io